In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-dependent cytotoxicity.

Nannini S, Sieffert C, McGown A, Gao XY, Jarvis A, Kostakis GE, Galvacsi A, Kallay C, Moraru R, Baud MG, Mandel S, Balourdas DI, Joerger AC, Orvain C, Peschard S, Nion A, Mellitzer G, Lottiaux S, Spencer J, Gross I, Gaiddon C